SIM-1803-1A

Phase Ia-Primary purpose: To evaluate the safety and tolerability of SIM1803-1A; To evaluate the pharmacokinetic characteristics of SIM1803-1A; To determine the maximum tolerated dose (MTD) of SIM1803-1A and the appropriate recommended dose (RD) for subsequent studies. Secondary purpose: To preliminarily evaluate the effectiveness of SIM1803-1A in treating patients with locally advanced/metastatic solid tumors with NTRK, ROS1 or ALK gene fusion mutations. Phase Ib-Primary purpose: To evaluate the effectiveness of SIM1803-1A in treating patients with locally advanced/metastatic solid tumors with NTRK, ROS1 or ALK gene fusion mutations. Secondary purpose: To evaluate the safety of SIM1803-1A in treating patients with locally advanced/metastatic solid tumors with NTRK, ROS1 or ALK gene fusion mutations; To evaluate the pharmacokinetic characteristics of SIM1803-1A at the recommended dose of Phase Ia.